Oligonucleotides, or short strands of DNA or RNA, continue to increase in popularity. In addition to their essential role as primers and probes in the expanding clinical DNA testing and diagnostics market, they’re also seeing… Read more >
In January of 2018, Waters kicked off its global Bioharmonization campaign with a blog post and video release, laying out a vision for how the Biopharmaceutical industry can achieve accelerated development and improved quality while… Read more >
Analytical data can be so much more than a historical point in time documented in a single report. In fact, biopharmaceutical organizations can use LC-MS data to build a continuum of compliance.
For biopharmaceutical organizations working with contract labs, it’s important to consider how data and methods will be transferred and how generated data will be managed so that it meets data integrity and compliance requirements.
Analytical methods transfer. Data integrity. A changing and more stringent regulatory landscape. All this, and more, impacts productivity in upstream and downstream biopharmaceutical processes. How is Waters looking to help address development challenges for biologics and biosimilars?
From oligonucleotides and peptides to messenger RNA and CRISPR, ’tides are enjoying their time in the sun A year ago we wrote how oligonucleotide therapeutic development, which had seen a huge wave of investment in… Read more >
Oligonucleotide drug development has seen its share of ups and downs over the past 20 years – but why? The promise of antisense oligonucleotides (ASOs) and later small interfering oligonucleotides (siRNAs) as therapeutics that can… Read more >